Cargando…
Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series
INTRODUCTION: It is generally believed that incretin-based therapies are effective in patients possessing certain levels of preserved β-cell function. So far, there are no reports that show the effectiveness of dipeptidyl peptidase-4 inhibitors in patients who absolutely lack the capacity for endoge...
Autor principal: | Kutoh, Eiji |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079672/ https://www.ncbi.nlm.nih.gov/pubmed/21443773 http://dx.doi.org/10.1186/1752-1947-5-117 |
Ejemplares similares
-
Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes
por: Giampietro, Ottavio, et al.
Publicado: (2013) -
Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes
por: Kishimoto, Miyako, et al.
Publicado: (2012) -
Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Wan, Heng, et al.
Publicado: (2016) -
A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes
por: Takai, Masahiko, et al.
Publicado: (2020) -
Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus
por: Katsuno, Tomoyuki, et al.
Publicado: (2016)